Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacy of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD) (TDACS)

11 giugno 2026 aggiornato da: Centre Hospitalier St Anne

Efficacy of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD): A Randomized Double-Blind Controlled Trial

Efficacy of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD): A Randomized Double-Blind Controlled Trial

Panoramica dello studio

Descrizione dettagliata

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by attentional difficulties and/or hyperactivity-impulsivity (American Psychiatric Association, 2013). Its treatment is primarily based on a multimodal approach, with first-line pharmacological management using methylphenidate (Ritalin®, Medikinet®, etc.).

However, given the limitations of pharmacological treatments (side effects, contraindications, and risks of misuse), alternative approaches such as transcranial direct current stimulation (tDCS) are generating increasing interest.

tDCS is a non-invasive, safe, and low-cost neuromodulation technique that delivers a low-intensity electrical current through electrodes placed on the scalp. It is well tolerated, with mild and transient adverse effects (tingling sensations, local skin redness, mild fatigue), making it a particularly safe approach. Its low cost and ease of use allow for broad accessibility, including in resource-limited healthcare settings.

In ADHD, tDCS targets the left dorsolateral prefrontal cortex, a key region involved in attention and executive functions. Early studies have reported encouraging results in terms of both efficacy and tolerability, particularly when combined with psychotherapeutic interventions.

The aim of this study is to evaluate the efficacy of tDCS in patients with ADHD.

The findings will support the potential future integration of tDCS into the management of ADHD resistant to conventional treatments.

Tipo di studio

Interventistico

Iscrizione (Stimato)

40

Fase

  • Non applicabile

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Adult patient aged 18 to 60 years inclusive
  • Patient diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD), combined or predominantly inattentive presentation, previously established by a healthcare professional
  • Patients must be registered in the active caseload of the Adult Neurodevelopmental Disorders Unit (STNDA)
  • Stable psychotropic medication regimen for at least four weeks prior to inclusion, in terms of both molecule and dosage, particularly for methylphenidate, or no current psychotropic treatment. Medication must remain unchanged throughout study participation, unless medically justified changes are required
  • Patient with a cognitive status deemed sufficient by the unit's referring psychiatrist to ensure appropriate completion of the scales and tests included in the protocol
  • Free, informed, and written consent

Exclusion Criteria:

•General condition impairment (severe fatigue or marked weakness, convalescence after an acute illness or surgery, or recent alcohol consumption)

Psychiatric and neurological disorders

  • Diagnosis of Autism Spectrum Disorder (ASD)
  • Diagnosis of personality disorder (Cluster A, B, C, or other), according to DSM-5-TR
  • Diagnosis of schizophrenia spectrum disorder or other psychotic disorders according to DSM-5-TR
  • Diagnosis of bipolar disorder with manic episode or history of manic episodes according to DSM-5-TR
  • Confirmed neurological disorder
  • Epilepsy or history of epileptic seizures

Medical comorbidities

  • Patient with known or suspected cardiac disease
  • Patient with severe pulmonary disease
  • Patient with cerebrovascular disease (e.g., stroke)

Dermatological and surgical contraindications

  • Patient with scalp lesions, open wounds, or skin conditions (severe acne, herpes, burns, skin fissures)
  • Patient with severe dermatitis, oozing eczema, or fragile scalp
  • Patient with major surgical scars
  • Patient with recent craniotomy

Implantable devices and materials

• Patient with a pacemaker or intracranial electrodes, presence of intracranial metal, or skull defects (e.g., post-craniectomy or trepanation without reconstruction)

Other criteria:

  • Simultaneous participation in another non-pharmacological intervention provided in the STNDA day hospital (e.g., psychoeducation, cognitive remediation, body expression therapy, emotional regulation training)
  • Patient with non-pathological ASRS screening scores (fewer than 4 of the first 6 items rated "Very often")
  • Insufficient proficiency in the French language
  • Patient under legal guardianship, curatorship, or judicial protection
  • Pregnant or breastfeeding patient (based on clinical interview)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore fittizio: tDCS sham
The placebo (sham) treatment will follow an identical protocol in terms of session duration, frequency, and overall procedure. Stimulation will be simulated, with a brief ramp-up and ramp-down of current at the beginning and end of the session, without actual stimulation during the remainder of the session, in order to mimic the initial sensations of active tDCS.

Repeated sessions of transcranial direct current stimulation (tDCS):

5 in-person tDCS sessions Intensity: 2.0 mA Duration: 20 minutes per session Frequency: 5 consecutive days Electrode placement: anode at F3 and cathode at F4

Sperimentale: tactive tDCS

Active transcranial direct current stimulation (tDCS): 2 mA stimulation for 20 minutes.

Repeated sessions of transcranial direct current stimulation (tDCS):

5 in-person tDCS sessions Intensity: 2.0 mA Duration: 20 minutes per session Frequency: 5 consecutive days Electrode placement: anode at F3 and cathode at F4

Repeated sessions of transcranial direct current stimulation (tDCS):

5 in-person tDCS sessions Intensity: 2.0 mA Duration: 20 minutes per session Frequency: 5 consecutive days Electrode placement: anode at F3 and cathode at F4

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Inattention Symptoms Assessed by the Adult ADHD Self-Report Scale (ASRS) from Baseline to Immediately After tDCS
Lasso di tempo: Baseline and immediately after the last tDCS session
The efficacy of tDCS will be assessed by measuring the change in inattention symptoms using the Adult ADHD Self-Report Scale (ASRS). The ASRS is a self-report questionnaire used to evaluate ADHD symptoms in adults. A decrease in the ASRS inattention score indicates an improvement in inattention symptoms.
Baseline and immediately after the last tDCS session

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Processing Speed Assessed by the WAIS-IV Coding and Symbol Search Subtests
Lasso di tempo: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Processing speed will be assessed using the Coding and Symbol Search subtests of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV). Changes in scores will be compared between the active tDCS group and the sham tDCS group.
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Change in Working Memory Assessed by the WAIS-IV Digit Span Subtest
Lasso di tempo: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Working memory will be assessed using the Digit Span subtest of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV). Changes in scores will be compared between the active tDCS group and the sham tDCS group.
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Change in Selective Attention Assessed by the d2-R Test of Attention
Lasso di tempo: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Selective attention will be assessed using the d2-R Test of Attention. Changes in attention performance scores will be compared between the active tDCS group and the sham tDCS group.
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Change in Emotional Regulation Assessed by the Difficulties in Emotion Regulation Scale - French Version (DERS-F)
Lasso di tempo: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Emotional regulation will be assessed using the Difficulties in Emotion Regulation Scale - French Version (DERS-F). Changes in emotional regulation scores will be compared between the active tDCS group and the sham tDCS group.
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Change in Anxiety and Depression Symptoms Assessed by the Hospital Anxiety and Depression Scale (HADS)
Lasso di tempo: Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Anxiety and depression symptoms will be assessed using the Hospital Anxiety and Depression Scale (HADS). Changes in anxiety and depression scores will be compared between the active tDCS group and the sham tDCS group.
Baseline, immediately after the last tDCS session, and 6 weeks after the last tDCS session
Incidence of Adverse Events Related to tDCS
Lasso di tempo: From the first tDCS session through 6 weeks after the last tDCS session
The safety and tolerability of tDCS will be assessed by comparing the frequency and nature of adverse events reported in the active tDCS group and the sham tDCS group.
From the first tDCS session through 6 weeks after the last tDCS session

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 giugno 2026

Completamento primario (Stimato)

10 giugno 2026

Completamento dello studio (Stimato)

20 febbraio 2028

Date di iscrizione allo studio

Primo inviato

21 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 giugno 2026

Primo Inserito (Effettivo)

17 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 giugno 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Disturbo da deficit di attenzione/iperattività (ADHD)

Prove cliniche su Transcranial direct current stimulation (tDCS)

Sottoscrivi